Jafron Biomedical Co Ltd (300529) - Total Liabilities
Based on the latest financial reports, Jafron Biomedical Co Ltd (300529) has total liabilities worth CN¥1.74 Billion CNY (≈ $254.12 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Jafron Biomedical Co Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
Jafron Biomedical Co Ltd - Total Liabilities Trend (2011–2025)
This chart illustrates how Jafron Biomedical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 300529 total assets.
Jafron Biomedical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jafron Biomedical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cury Construtora e Incorporadora S.A
SA:CURY3
|
Brazil | R$3.99 Billion |
|
Lakefront Biotherapeutics NV
NASDAQ:LKFT
|
USA | $87.52 Million |
|
Shenzhen Topband Co Ltd
SHE:002139
|
China | CN¥6.61 Billion |
|
ISC Co. Ltd
KQ:095340
|
Korea | ₩78.49 Billion |
|
Vukile Property Fund Ltd
JSE:VKE
|
South Africa | ZAC26.77 Billion |
|
Austevoll Seafood ASA
OL:AUSS
|
Norway | Nkr24.28 Billion |
|
Ningxia Jiaze Renewables Corp
SHG:601619
|
China | CN¥14.81 Billion |
|
Xiamen ITG Group Corp Ltd
SHG:600755
|
China | CN¥102.92 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Jafron Biomedical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 300529 net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jafron Biomedical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jafron Biomedical Co Ltd (2011–2025)
The table below shows the annual total liabilities of Jafron Biomedical Co Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.94 Billion ≈ $283.54 Million |
-5.43% |
| 2024-12-31 | CN¥2.05 Billion ≈ $299.80 Million |
-14.29% |
| 2023-12-31 | CN¥2.39 Billion ≈ $349.79 Million |
+31.13% |
| 2022-12-31 | CN¥1.82 Billion ≈ $266.76 Million |
+27.80% |
| 2021-12-31 | CN¥1.43 Billion ≈ $208.74 Million |
+272.38% |
| 2020-12-31 | CN¥383.06 Million ≈ $56.05 Million |
+18.18% |
| 2019-12-31 | CN¥324.13 Million ≈ $47.43 Million |
-1.79% |
| 2018-12-31 | CN¥330.04 Million ≈ $48.30 Million |
+6.16% |
| 2017-12-31 | CN¥310.90 Million ≈ $45.49 Million |
+168.46% |
| 2016-12-31 | CN¥115.81 Million ≈ $16.95 Million |
-7.06% |
| 2015-12-31 | CN¥124.61 Million ≈ $18.23 Million |
+43.91% |
| 2014-12-31 | CN¥86.59 Million ≈ $12.67 Million |
+6.11% |
| 2013-12-31 | CN¥81.60 Million ≈ $11.94 Million |
+60.83% |
| 2012-12-31 | CN¥50.74 Million ≈ $7.42 Million |
+65.41% |
| 2011-12-31 | CN¥30.68 Million ≈ $4.49 Million |
-- |
About Jafron Biomedical Co Ltd
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machi… Read more